Skip to Content
 

Emerging Markets Panel

“Achieving Market Access and Favorable Investment Returns in Developing Healthcare Markets”

ISSUES

  • Current opportunities & barriers/risks for global healthcare companies investing in, and marketing to, emerging markets (China, India, Brazil, Russia, Turkey, others).
  • Trends and examples of innovative cross-border deals in these regions, including R&D collaborations.    
  • How health reform initiatives in emerging markets (e.g., China) are impacting the healthcare dynamics in these markets (payors, providers, manufacturers)? Will the IP environment improve or worsen in these key markets?
  • What pricing environment and profit margins are being assumed by global products companies for key markets in this region? Will innovation be rewarded by payors in these markets?
  • How will the emerging market healthcare landscape shape-up in the next 3-5 years, including relative importance of China, India, Brazil, etc.?

 

Peter Barschdorff '05 (EMBA)
Vice President
Bayer Business Consulting

Peter Barschdorff is Head of Bayer Business Consulting North America, and Deputy Head of Bayer Business Consulting (global). His career spans 15 years of management consulting, including in management positions at Deloitte Consulting and Capgemini Consulting, where he advised senior executives of leading global manufacturers on strategy and transformation topics.

Peter’s main industry focus is Healthcare and Pharmaceuticals, with a primary focus on the Commercial functions. Peter has led engagements on five continents and for all major pharmas, including new sales model, marketing innovation, public policy, alliance strategy, as well as outsourcing/ offshoring.

In his current role at Bayer, his main focus is on corporate governance, commercial strategies and operations improvement. During his earlier time as interim Head of Bayer Business Consulting APAC (China), he was responsible for engagements in post-merger integration, corporate governance, product launch, and sales effectiveness.

Peter holds a Ph.D. in International Relations from the Free University of Berlin as well as an MBA from Columbia Business School.

Petra Danielsohn-Weil, PhD
VP Strategy & Commercial Solutions, Emerging Markets and Established Products Business Units
Pfizer

Petra Danielsohn-Weil is Vice President, Strategy and Commercial Solutions, Emerging Markets and Established Products Business Units for Pfizer. She leads a team that includes strategy, global pricing, market access, business development and operations functions. Prior to her current role, Petra was Regional President of Northern Central Europe for the Established Products Business Unit, Country Manager of Switzerland, and VP Sales for Germany among other management positions.  Petra started with Warner-Lambert (acquired by Pfizer) in 1988 in the sales and marketing division and held various positions of increasing responsibility including Director of Business Development for the German region and CEER, Product Director with international marketing responsibilities out of the home office in New Jersey, National Sales Director for Parke-Davis Germany, and head of the Company’s business unit in Germany covering all key franchises (pain, CNS, cardiovascular, diabetes, and specialty businesses).

Petra holds a Ph.D. in Natural Science, Biology and Chemistry from University of Muenster in Germany.

 

Ellie Pidot
Vice President, Strategy
Medtronic

Ellie Pidot is Vice President, Strategy at Medtronic.  In this role, Ellie leads the development of Medtronic’s corporate strategy, including aspiration and target-setting, portfolio management, resource allocation, and key enterprise-wide strategic initiatives.  Prior to her role in Strategy, Ellie served as Vice President, Office of the Chairman and CEO, where she worked with Medtronic’s CEO, Executive Committee, and Board of Directors to improve the impact and effectiveness of strategic decision-making and execution across the company.

Prior to joining Medtronic, Ellie was a consultant at McKinsey & Company, where she served healthcare clients and counseled senior executives on issues of strategy, growth, organization, M&A, and sales and marketing.

Ellie has a JD from the University of Virginia SchooL of Law, an MBA from the Darden School of Business, and an AB, cum laude in Government, from Harvard College.  She is admitted to the Bar in New York and Minnesota.

Outside of work, Ellie enjoys playing golf and tennis, waterskiing, and coaching her 4-year-old daughter Loraine’s soccer team.

Adam Sohn '04
VP Market Access / Pricing & Reimbursement
IMS Consulting

Adam Sohn joined the Pricing and Market Access practice of IMS Consulting in 2004 and has supported both large and small biopharmaceutical companies with the commercialization of niche and blockbuster drugs. His experience developing payer strategies extends 5 continents and has covered multiple therapeutic areas including but not exclusive to cardiovascular disease, hypercholesterolemia, migraine, oncology, osteoporosis, diabetes, anti-infectives, and vaccines. Adam has global expertise with launch pricing, innovative pricing, contracting, and market access strategies for community and especially hospital-based products. In the US, he has also focused on strategies to address the evolving payer and policy environment, including Medicare and healthcare coverage reform.  Within the emerging markets, Adam has similarly worked extensively on policy, access, and commercial opportunity assessments for pharmaceuticals and biologics.

Before joining IMS Consulting, Adam was an Associate equity analyst at CIBC World Markets covering the large and specialty pharmaceutical sectors and a healthcare management consultant at Ernst & Young Consulting, now Cap Gemini. 

Adam holds an MBA from Columbia Business School and an undergraduate degree in Political Economy from Princeton University.

Andre Turenne
Vice President and Global Head of Strategy & Business Development
Genzyme, a Sanofi Company

Andrew joined Genzyme in 2006 and has held global positions of increasing responsibility in business development, portfolio planning, and commercial operations across multiple businesses.  Prior to the merger with Sanofi, he served as Head of Global Commercial Operations for the $1B Renal business unit, with sales in over seventy countries.  After playing a leadership role in the merger integration efforts, he was appointed to lead the rare disease business development efforts before taking on his current responsibilities.  His emerging market transactional experience includes negotiating collaboration agreements with companies and research organizations in China, Brazil, and Russia.  Prior to Genzyme, he was a strategy consultant advising clients at private and public life sciences companies.  Andre received his BA from Kalamazoo College and his MBA from the Tuck School of Business at Dartmouth.